VJOncology is committed to improving our service to you

ESMO 2018 | Denosumab for NSCLC: results from SPLENDOUR

VJOncology is committed to improving our service to you

Solange Peters

Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, gives us an update on the ETOP and EORTC SPLENDOUR trial (NCT02129699) of denosumab for advanced non-small cell lung cancer.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter